ReviewMolecules (Basel, Switzerland)2015
Pharmaceutical Potential of Synthetic and Natural Pyrrolomycins.
Review in Molecules (Basel, Switzerland), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Broad-Spectrum Anti-Infective Activity of Natural Compounds Pyrrolomycins, Marinopyrroles, and Their Analogs.Pathogens (Basel, Switzerland) · 2026Review
- Marine-derived Bioactive Compounds: A Promising Frontier against Multidrug-resistant Microbial Infections.Mini reviews in medicinal chemistry · 2026Review
- Cancer Cell Cytotoxicity of Marinopyrroles, Pyrrolomycins, and Their Derivatives.Marine drugs · 2025Review
- Isolation of Halophilic and Halotolerant Bacterial Strains, Screening for Bioactive Compounds and Characterisation of Metabolites Produced by Pseudoalteromonas sp. ASV78.Environmental microbiology reports · 2025Article
- Unlocking the Potential of Pyrrole: Recent Advances in New Pyrrole-Containing Compounds with Antibacterial Potential.International journal of molecular sciences · 2024Review
- Fructose promotes pyoluteorin biosynthesis via the CbrAB-CrcZ-Hfq/Crc pathway in the biocontrol strainSynthetic and systems biotechnology · 2023Article
- Total synthesis and mechanism of action of the antibiotic armeniaspirol A.Chemical science · 2021Article
- Synthesis of novel pyrroles and fused pyrroles as antifungal and antibacterial agents.Journal of enzyme inhibition and medicinal chemistry · 2021Article
- Pyrrolidine in Drug Discovery: A Versatile Scaffold for Novel Biologically Active Compounds.Topics in current chemistry (Cham) · 2021Review
- Targeting Bacterial Sortases in Search of Anti-Virulence Therapies with Low Risk of Resistance Development.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Bioactive pyrrole-based compounds with target selectivity.European journal of medicinal chemistry · 2020Review
- In-Silico Identified New Natural Sortase A Inhibitors DisruptInternational journal of molecular sciences · 2020Article
- New Synthetic Nitro-Pyrrolomycins as Promising Antibacterial and Anticancer Agents.Antibiotics (Basel, Switzerland) · 2020Article
- Investigating the Biosynthesis of Natural Products from Marine Proteobacteria: A Survey of Molecules and Strategies.Marine drugs · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The emergence of antibiotic resistance is currently considered one of the most important global health problem. The continuous onset of multidrug-resistant Gram-positive and Gram-negative bacterial strains limits the clinical efficacy of most of the marketed antibiotics. Therefore, there is an urgent need for new antibiotics. Pyrrolomycins are a class of biologically active compounds that exhibit a broad spectrum of biological activities, including antibacterial, antifungal, anthelmintic, antiproliferative, insecticidal, and acaricidal activities. In this review we focus on the antibacterial activity and antibiofilm activity of pyrrolomycins against Gram-positive and Gram-negative pathogens. Their efficacy, combined in some cases with a low toxicity, confers to these molecules a great potential for the development of new antimicrobial agents to face the antibiotic crisis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.